Following secretive AbCellera pact, Moderna picks up another antibody discovery deal via Harbour BioMed
As it moves to position itself beyond pandemic stardom, Moderna is spidering out into a number of biotech spheres — working on an Ebola vaccine, looking into the next iteration of cancer cell therapies and spending on an antibody discovery partnership.
In its latest move, Moderna is adding another antibody discovery collaboration — this time with Harbour BioMed through its new subsidiary Nona Biosciences, it announced Friday. Harbour sports a platform that specifically develops heavy chain-only antibodies, which it says are half the size of traditional antibodies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.